TipRanks

Notifications

BTIG Thinks Homology Medicines’ Stock is Going to Recover

BTIG analyst Robert Hazlett reiterated a Buy rating on Homology Medicines (FIXXResearch Report) on October 12 and set a price target of $35.00. The company’s shares closed last Wednesday at $6.20, close to its 52-week low of $5.94.

According to TipRanks.com, Hazlett is a 4-star analyst with an average return of 20.8% and a 43.0% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Eiger Biopharmaceuticals, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Homology Medicines is a Strong Buy with an average price target of $27.00, representing a 309.1% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

Homology Medicines’ market cap is currently $353.9M and has a P/E ratio of -3.70. The company has a Price to Book ratio of 1.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Read More on FIXX:

Tags: